AMGEN INC
For the period ended Mar 31, 2024. Filed May 3, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 3, 2024
AMGN$465.230.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
| Three months endedMarch 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net (loss) income | $(113) | $2,841 |
| Depreciation, amortization and other | 1,399 | 900 |
| Stock-based compensation expense | 103 | 47 |
| Deferred income taxes | (401) | (49) |
| Adjustments for equity method investments | (27) | (31) |
| Losses (gains) on equity securities | 515 | (1,830) |
| Other items, net | (95) | (60) |
| Changes in operating assets and liabilities, net of acquisitions: | ||
| Trade receivables, net | 486 | (144) |
| Inventories | 806 | (58) |
| Other assets | (89) | (139) |
| Accounts payable | 23 | (253) |
| Accrued income taxes, net | 223 | 443 |
| Long-term tax liabilities | (715) | 107 |
| Accrued liabilities | (1,054) | (230) |
| Accrued sales incentives and allowance | (316) | (402) |
| Other liabilities | (56) | (78) |
| Net cash provided by operating activities | 689 | 1,064 |
| Cash flows from investing activities: | ||
| Proceeds from sales of marketable securities | — | 1,124 |
| Proceeds from maturities of marketable securities | — | 550 |
| Purchases of property, plant and equipment | (230) | (344) |
| Other | 13 | 28 |
| Net cash (used in) provided by investing activities | (217) | 1,358 |
| Cash flows from financing activities: | ||
| Net proceeds from issuance of debt | — | 23,798 |
| Extinguishment of debt | (410) | (420) |
| Repayment of debt | — | (704) |
| Dividends paid | (1,208) | (1,137) |
| Other | (90) | (28) |
| Net cash (used in) provided by financing activities | (1,708) | 21,509 |
| (Decrease) increase in cash and cash equivalents | (1,236) | 23,931 |
| Cash and cash equivalents at beginning of period | 10,944 | 7,629 |
| Cash and cash equivalents at end of period | $9,708 | $31,560 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.